在BRCA之后的20年:在个性化癌症护理和预防方面树立范例
Fergus J Couch1, Katherine L Nathanson, Kenneth Offit
1Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
对BRCA1和BRCA2突变的基因测试有助于识别患乳腺癌高风险个体. 这使得个性化查,预防和有针对性的治疗选择能够获得更好的患者护理.
科学领域:
- 基因组学就是基因组学.
- 在瘤学瘤学.
- 临床遗传学 临床遗传学
背景情况:
- 鉴定BRCA1和BRCA2基因彻底改变了癌症风险评估.
- 基因检测对于管理遗传性乳腺癌风险至关重要.
研究的目的:
- 审查BRCA1和BRCA2的遗传突变.
- 讨论变种病原性评估中的挑战.
- 概述突变载体的临床管理策略.
主要方法:
- 关于BRCA1/2突变和临床管理的文献综述.
- 对癌症护理中的基因测试应用的分析.
- 讨论风险评估的复杂性.
主要成果:
- 通过BRCA1/2测试,可以确定符合加强查和预防的个人.
- 基因信息指导了向治疗的选择.
- 变异性致病性的不确定性使风险确定变得复杂.
结论:
- 对BRCA1/2突变的基因检测是遗传性乳腺癌管理的组成部分.
- 有效的临床策略对于BRCA1/2突变的女性至关重要.
更多相关视频
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
09:24Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
Cancer Prevention
Some...
Cancer Prevention
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
